165 related articles for article (PubMed ID: 28105232)
1. TRIP13 is expressed in colorectal cancer and promotes cancer cell invasion.
Kurita K; Maeda M; Mansour MA; Kokuryo T; Uehara K; Yokoyama Y; Nagino M; Hamaguchi M; Senga T
Oncol Lett; 2016 Dec; 12(6):5240-5246. PubMed ID: 28105232
[TBL] [Abstract][Full Text] [Related]
2. TRIP13 promotes proliferation and invasion of epithelial ovarian cancer cells through Notch signaling pathway.
Zhou XY; Shu XM
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):522-529. PubMed ID: 30720159
[TBL] [Abstract][Full Text] [Related]
3. TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer.
Sheng N; Yan L; Wu K; You W; Gong J; Hu L; Tan G; Chen H; Wang Z
Cell Death Dis; 2018 Mar; 9(3):402. PubMed ID: 29540729
[TBL] [Abstract][Full Text] [Related]
4. TRIP13, identified as a hub gene of tumor progression, is the target of microRNA-4693-5p and a potential therapeutic target for colorectal cancer.
Chen Y; Chen D; Qin Y; Qiu C; Zhou Y; Dai M; Li L; Sun Q; Jiang Y
Cell Death Discov; 2022 Jan; 8(1):35. PubMed ID: 35075117
[TBL] [Abstract][Full Text] [Related]
5. TRIP13 Activates Glycolysis to Promote Cell Stemness and Strengthen Doxorubicin Resistance of Colorectal Cancer Cells.
Liu G; Wang H; Rui R; Wang Y; Li Y
Curr Med Chem; 2024 Feb; ():. PubMed ID: 38347785
[TBL] [Abstract][Full Text] [Related]
6. Thyroid Receptor-Interacting Protein 13 is Correlated with Progression and Poor Prognosis in Bladder Cancer.
Niu L; Gao Z; Cui Y; Yang X; Li H
Med Sci Monit; 2019 Sep; 25():6660-6668. PubMed ID: 31486418
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of thyroid hormone receptor interactor 13 is associated with human hepatocellular carcinoma.
Ju L; Li X; Shao J; Lu R; Wang Y; Bian Z
Oncol Rep; 2018 Dec; 40(6):3794-3802. PubMed ID: 30542731
[TBL] [Abstract][Full Text] [Related]
8. TRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancer.
Dong L; Ding H; Li Y; Xue D; Li Z; Liu Y; Zhang T; Zhou J; Wang P
Int J Biol Macromol; 2019 Jan; 121():200-206. PubMed ID: 30267820
[TBL] [Abstract][Full Text] [Related]
9. Loss of thyroid hormone receptor interactor 13 inhibits cell proliferation and survival in human chronic lymphocytic leukemia.
Zhou K; Zhang W; Zhang Q; Gui R; Zhao H; Chai X; Li Y; Wei X; Song Y
Oncotarget; 2017 Apr; 8(15):25469-25481. PubMed ID: 28424416
[TBL] [Abstract][Full Text] [Related]
10. Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4.
Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB
J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816
[TBL] [Abstract][Full Text] [Related]
11. The oncogenic role of TRIP13 in regulating proliferation, invasion, and cell cycle checkpoint in NSCLC cells.
Zhang Q; Dong Y; Hao S; Tong Y; Luo Q; Aerxiding P
Int J Clin Exp Pathol; 2019; 12(9):3357-3366. PubMed ID: 31934178
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway.
Gao Y; Liu S; Guo Q; Zhang S; Zhao Y; Wang H; Li T; Gong Y; Wang Y; Zhang T; Dong Z; Bacich D; Chowdhury WH; Rodriguez R; Wang Z
Int J Biol Sci; 2019; 15(7):1488-1499. PubMed ID: 31337978
[TBL] [Abstract][Full Text] [Related]
13. Elevated TRIP13 drives cell proliferation and drug resistance in bladder cancer.
Lu S; Guo M; Fan Z; Chen Y; Shi X; Gu C; Yang Y
Am J Transl Res; 2019; 11(7):4397-4410. PubMed ID: 31396344
[TBL] [Abstract][Full Text] [Related]
14. Targeting TRIP13 for overcoming anticancer drug resistance (Review).
Zhao L; Ye S; Jing S; Gao YJ; He T
Oncol Rep; 2023 Nov; 50(5):. PubMed ID: 37800638
[TBL] [Abstract][Full Text] [Related]
15. TRIP13 is a protein-remodeling AAA+ ATPase that catalyzes MAD2 conformation switching.
Ye Q; Rosenberg SC; Moeller A; Speir JA; Su TY; Corbett KD
Elife; 2015 Apr; 4():. PubMed ID: 25918846
[TBL] [Abstract][Full Text] [Related]
16. Mode of interaction of TRIP13 AAA-ATPase with the Mad2-binding protein p31comet and with mitotic checkpoint complexes.
Miniowitz-Shemtov S; Eytan E; Kaisari S; Sitry-Shevah D; Hershko A
Proc Natl Acad Sci U S A; 2015 Sep; 112(37):11536-40. PubMed ID: 26324890
[TBL] [Abstract][Full Text] [Related]
17. Insights into a Crucial Role of TRIP13 in Human Cancer.
Lu S; Qian J; Guo M; Gu C; Yang Y
Comput Struct Biotechnol J; 2019; 17():854-861. PubMed ID: 31321001
[TBL] [Abstract][Full Text] [Related]
18. TRIP13 interference inhibits the proliferation and metastasis of thyroid cancer cells through regulating TTC5/p53 pathway and epithelial-mesenchymal transition related genes expression.
Yu L; Xiao Y; Zhou X; Wang J; Chen S; Peng T; Zhu X
Biomed Pharmacother; 2019 Dec; 120():109508. PubMed ID: 31648166
[TBL] [Abstract][Full Text] [Related]
19. TRIP13 Regulates Both the Activation and Inactivation of the Spindle-Assembly Checkpoint.
Ma HT; Poon RYC
Cell Rep; 2016 Feb; 14(5):1086-1099. PubMed ID: 26832417
[TBL] [Abstract][Full Text] [Related]
20. Mad2 Overexpression Uncovers a Critical Role for TRIP13 in Mitotic Exit.
Marks DH; Thomas R; Chin Y; Shah R; Khoo C; Benezra R
Cell Rep; 2017 May; 19(9):1832-1845. PubMed ID: 28564602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
